TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06203899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Op Volle Kracht
Description: This is a preventive group training based on cognitive behavioural therapy for depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gatekeeperstraining
Description: This is a training for teachers to detect and address depressive symptoms and suicidality in their students .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gatekeeperstraining
Description: This is a training for teachers to detect and address depressive symptoms and suicidality in their students .
Study: NCT06014684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timing of exercise
Description: High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timing of exercise
Description: High Intensity Interval Training (HIIT) program for 12 weeks (3 per week/36 sessions in total)
Study: NCT05038813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib+TQB2450
Description: Anlotinib: 12mg, orally once a day (orally before breakfast, the daily medication time should be as the same as possible), continuous taking for 2 weeks, stopping for 1 week, 3 weeks (21 days) as a treatment cycle, until the disease progresses or Intolerable.~TQB2450: 1200mg, diluted to 250mL with normal saline, infusion time 60±10mins. The medication is taken on the first day of each cycle, and 3 weeks (21 days) is a treatment cycle. Until the emergence of disease progression or intolerable toxicity, the longest use time does not exceed 24 months.
Study: NCT04860830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study: NCT05702177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.
Study: NCT04860830

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05702177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.
Study: NCT06255015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding toolkit card
Description: The card is delivered at 24 weeks and is also referred to in the 32 and 36 week antenatal meetings. It will also be referred to in the first 24 hours post-partum and in home visits.
Study: NCT06350266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information about healthcare resources
Description: Text messages will be sent following discharge from the emergency department; text may also be modified in the (online and/or printed) discharge summary packet.
Study: NCT05316311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CERENOVUS ENTERPRISE 2 Intracranial Stent
Description: CERENOVUS ENTERPRISE 2 Intracranial Stent will be used to treat severe symptomatic intracranial artery stenosis.
Study: NCT05576038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Tryptophan
Description: L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Freedom SimpleCap Powder
Description: Freedom SimpleCap Powder is a high functionality capsule and tablet excipient composite comprised of filler, glidant, disintegrant and lubricant (ingredients include: Microcrystalline Cellulose, Silicon Dioxide Colloidal, Sodium Starch Glycolate, Sodium Stearyl Fumarate). This capsule is dye, lactose and gluten free and will not interfere with the AhR pathway. Freedom SimpleCap Powder makes oral capsule formulation convenient, quick and simple Thus, this SimpleCap Powder will be an appropriate placebo comparator for this study.
Study: NCT05582551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Highlighting Patients at Risk for Sensory Screening (HPARSS)
Description: Collaborators in the Informatics Research branch of the Institute of Informatics at the Washington University School of Medicine will identify CCS at risk for sensory deficits based upon their therapy exposure to generate the HPARSS document.
Study: NCT05716984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human brain natriuretic peptide
Description: rhBNP 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 500μg + 0.9% sodium chloride 50ml, the concentration is 10 μg/ml, loading dose 1.5 μg/kg iv, followed by 0.0075 μg/kg·min with micro-pump injection for 72 hours.
Study: NCT05331755

Intervention type: DRUG
Intervention: Dupilumab
Description: start medication in cohort
Study: NCT05590897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teeth Brushing
Description: All 52 participants were instructed through a lecture on how to perform toothbrushing with a fluoridated toothpaste (Colgate T®) and dental flossing three times per day after meals for 30 days. The Bass technique was taught, by which the bristles should be positioned at an approximate angle of 45º to the gingival pocket on both the free and proximal faces, with the performance of short, slightly circular vibrating movements.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teeth Brushing
Description: All 52 participants were instructed through a lecture on how to perform toothbrushing with a fluoridated toothpaste (Colgate T®) and dental flossing three times per day after meals for 30 days. The Bass technique was taught, by which the bristles should be positioned at an approximate angle of 45º to the gingival pocket on both the free and proximal faces, with the performance of short, slightly circular vibrating movements.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Flossing
Description: All 52 participants were instructed to floss, 3 times a day after meals for 30 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Flossing
Description: All 52 participants were instructed to floss, 3 times a day after meals for 30 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue Scraping
Description: Tongue scraping was performed by the same operator for all participants. Posteroanterior movements were performed with the scraper on the dorsum of the tongue, followed by the cleaning of the scraper with gauze. The procedure was performed ten times on each participant to standardize mechanical removal.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic Therapy (aPDT)
Description: One session of aPDT was performed. The annatto photosensitizer was mixed at a concentration of 20% (Fórmula e Ação®, Brazil) in spray form, applied with a sufficient quantity to coat the middle third of the dorsum of the tongue (five sprays) and left for two minutes for incubation. The excess was removed with an aspirator. \|The surface of the tongue remained moist with the photosensitizer itself without the use of water. Six points were irradiated with a distance of 1 cm between points, considering the spread of the light and effectiveness of aPDT. The device was previously calibrated at a wavelength of 395-480 nm. Light was irradiated to ensure a beam area of 2 cm in diameter per point. Energy was 9.6 J and exposure time was 20 seconds per point.
Study: NCT06194851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Veteran participants will self-administer 40 IU of intranasal oxytocin 30 minutes before the start of each bCBCT session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline nasal spray
Description: Veteran participants will self-administer 40 IU of the placebo (intranasal saline spray) 30 minutes before the start of each bCBCT session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioral Conjoint Therapy
Description: Eight sessions of standardized bCBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Cognitive-Behavioral Conjoint Therapy
Description: Eight sessions of standardized bCBCT, a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning.
Study: NCT05548205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Glucose Monitor
Description: Self-administered according to investigator instruction.
Study: NCT05274841

Intervention type: OTHER
Group type: OTHER
Intervention: Support of relatives
Description: Screening of the support needs of relatives
Study: NCT04936802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve repair system (Trialign)
Description: To assess the Trialign System to treat subjects with moderate to severe tricuspid regurgitation
Study: NCT05103280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistive tennis shoes
Description: Assistive shoes include carbon-fiber and spring loaded shoes.
Study: NCT05919225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Risk stratification before decision-making about patient hospitalization or discharge
Description: Once AHF has been diagnosed at ED, and before decision-making about hospitalize/discharge home is taken, physicians will objectively measure the severity of decompensation, based on risk of 30-day death using MEESSI scale. As result, patient can be allocated to low, intermediate, high or very-high risk. For patients classified as low-risk, the propocol recommendation will be discharge patient to home. For patients classified as increased risk (i.e., intermediate, high or very-high risk categories), the protocol recommendation will be to hospitalize patient. Nonetheless, final decission will be left to emergency physician, and overruling (disposition against recommendation) will be allowed.
Study: NCT04916964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test and exercise home-based program
Description: Eight home-based physiotherapy sessions will occur in two months, once a week, to activate the preserved implicit memory (PIM). The recommendations are to train three weeks with the same exercise program, three times a week (one time coached by the attributed physiotherapist and two times coached by a natural or family caregiver). After three weeks, the participants can choose if they want to keep the same exercises or change all or some of these, in testing other tasks. Every training session will be planned to last 45 minutes. During each training session, the participant will note on his/her own Training booklet each task performed. The Training booklet will be used to plane, organize, and remember details for the next training session.
Study: NCT03770299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Specified dose on specified days
Study: NCT06197906

Intervention type: DEVICE
Group type: OTHER
Intervention: Device implant
Description: subcutaneous device implanting
Study: NCT05977894

Intervention type: OTHER
Intervention: Reduced Environmental Stimulation Therapy
Description: During floatation-REST (Reduced Environmental Stimulation Therapy), the participant enters a tank that is approximately 5 feet wide, 7 feet long and 5 feet high. The tank is filled with a 10 inch height of water containing enough Epsom salt (magnesium sulfate) to create body buoyancy. The water temperature is 93.5 degrees F, an approximate equivalent for normal skin temperature. Ear plugs are used to mitigate sound and the tank is without light illumination to prevent visual stimulation. The sessions are typically 60 minutes in duration. The individual is Floating-in Solitude, Darkness, Silence, and Thermal-Neutrality. This experience reduces external sensory nervous system input and creates an extraordinarily deep state of mental and physical relaxation.
Study: NCT05276167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperthermic intravesical perfusion
Description: Participants in the experimental group will be treated with hyperthermic intravesical perfusion before receiving radical cystectomy
Study: NCT05282290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (no restriction on the type of drugs)
Description: The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive drugs (no restriction on the type of drugs)
Description: The division of care unit doctors and nurses is clear, the former is responsible for giving medical advice, the latter is responsible for carrying it out.~The experimental group and the control group were given intravenous antihypertensive drugs (no restriction on the type of drugs), and their blood pressure reached the standard within 2 hours after vascular opening.
Study: NCT05263297

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: no intervention will be made.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: no intervention will be made.
Study: NCT06483425

Intervention type: GENETIC
Intervention: Sequencing of DNA, RNA, and Proteins
Description: Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
Study: NCT03770299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Specified dose on specified days
Study: NCT06425848

Intervention type: DEVICE
Intervention: Observational
Description: We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.

Intervention type: DEVICE
Intervention: Observational
Description: We are collecting information for both retrospective and prospective arm to further understand the utility of PA pressure sensors.
Study: NCT03770299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study: NCT05809674

Intervention type: DEVICE
Intervention: Polarization sensitive optical coherence tomography (PS-OCT)
Description: The PS-OCT is a prototype, also known as an early version of a medical device, specially developed by the Ocular Imaging Research Group, Singapore Eye Research Institute, for prediction of myopia progression. It has not been approved for use in any other country. There is currently no method to identify who is at risk of myopia progression. The PS-OCT device will provide the capabilities of OCT scleral biomarkers, which may have the potential to identify individuals at high risk for myopia.
Study: NCT06472336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial stenting
Description: Intracranial stenting (+/- balloon dilatation) will be performed. Decisions regarding intracranial stenting are solely made by the treating physician. This means in specific, that the treating physician decides based on his/her judgement or based on local standards (as reported in the literature) on the devices and/or concomitant medications (including infusion/administration of antiplatelet medicine) used for intracranial stenting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of conventional endovascular therapy (EVT)
Description: Patients undergo either (a) continued stent retriever or contact aspiration based endovascular treatment manoeuvres, (b) infusion/administration of antiplatelet medication or (c) stop of the procedure depending on local standard treatment approaches.
Study: NCT05802186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology, Treatment Planning
Description: Undergo radiation planning with AI-directed analysis for dose recommendation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT05586464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ban xia xie xin Decoction and bismuth quadruplicate group
Description: Ban xia xie xin Decoction:10g of banxia, 10g of huangqin, 6g of coptis chinensis, 6g of dried ginger, 6g of ginseng, 6g of roasted licorice, 6g of Chinese jujube Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth quadruplicate group
Description: Bismuth quadruplicate: Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid), amoxicillin ( Tablets 25mg/tablet,100mg bid), furazolidone (Tablets100mg/tablet,100mg bid) and pectin bismuth gel (Gel 150mg/bag, 150mg qid).
Study: NCT05249062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAPES app
Description: Participants will be asked to use the app and connected devices daily for 3 months.
Study: NCT05683717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01488 Tablets
Description: TT-01488 tablet will be administered orally once daily per protocol defined schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-01488 Tablets
Description: TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Study: NCT04895514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma-irradiated corneal tissue inlay
Description: A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of gamma-irradiated preserved corneal tissue will then be placed into the pocket
Study: NCT03770299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study: NCT05412810

Intervention type: OTHER
Intervention: oxygen
Description: oxygen exposure of more than 50% for 1.5 hours
Study: NCT06069999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandyMotion Treatment Program
Description: A pair of sensor-based wireless remote controllers to allow the performance of functional exercises and games that target arm movement.
Study: NCT05047263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: Tablet, 10 mg or 20 mg, once daily (OD), oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, once daily, oral
Study: NCT05268081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual specialist conferences
Description: The intervention consists of four virtual conferences (45 min each in month 2, 5, 8 and 11) and an introductory webinar (90 min in month 1) to learn GPs about how to use the electronic Diabetes Overview to identify and manage patients with T2D. Each general practice is assigned to one specific endocrinologist they meet with throughout. The four virtual conferences are thematic: T2D and cardiovascular disease and heart failure, T2D and lipids, T2D and kidney disease and blood pressure, and T2D and a free topic selected by the GP. At each conference, the GP must bring 2-3 patient cases related to the theme and 1-2 patients of their own choice. The GP chairs the meeting. Each conference follows the same format: Check in (5 min); Short presentation by the endocrinologist (10 min); Presentation by GP and joint dialogue about theme-related patients (20 min); Presentation by GP and joint dialogue about theme-unrelated patients (optional, 5 min); (5) Wrapping-up (5 min).
Study: NCT05537025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-MMP7 Inhalation Solution
Description: ARO-MMP7 by inhalation of nebulized solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution
Study: NCT06391489

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HOBSCOTCH-PACS
Description: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH) HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
Study: NCT06384612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: use of pocket cards
Description: Use of pocket cards of 22 cm x 11 cm size prepared by students every week in classes